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Background: Foot disease complications, such as foot ulcers and infection, contribute to considerable morbidity
and mortality. These complications are typically precipitated by “high-risk factors”, such as peripheral neuropathy
and peripheral arterial disease. High-risk factors are more prevalent in specific “at risk” populations such as diabetes,
kidney disease and cardiovascular disease. To the best of the authors’ knowledge a tool capturing multiple high-risk
factors and foot disease complications in multiple at risk populations has yet to be tested. This study aimed to
develop and test the validity and reliability of a Queensland High Risk Foot Form (QHRFF) tool.
Methods: The study was conducted in two phases. Phase one developed a QHRFF using an existing diabetes foot
disease tool, literature searches, stakeholder groups and expert panel. Phase two tested the QHRFF for validity and
reliability. Four clinicians, representing different levels of expertise, were recruited to test validity and reliability.
Three cohorts of patients were recruited; one tested criterion measure reliability (n = 32), another tested criterion
validity and inter-rater reliability (n = 43), and another tested intra-rater reliability (n = 19). Validity was determined
using sensitivity, specificity and positive predictive values (PPV). Reliability was determined using Kappa, weighted
Kappa and intra-class correlation (ICC) statistics.
Results: A QHRFF tool containing 46 items across seven domains was developed. Criterion measure reliability of at
least moderate categories of agreement (Kappa > 0.4; ICC > 0.75) was seen in 91% (29 of 32) tested items. Criterion
validity of at least moderate categories (PPV > 0.7) was seen in 83% (60 of 72) tested items. Inter- and intra-rater
reliability of at least moderate categories (Kappa > 0.4; ICC > 0.75) was seen in 88% (84 of 96) and 87% (20 of 23)
tested items respectively.
Conclusions: The QHRFF had acceptable validity and reliability across the majority of items; particularly items
identifying relevant co-morbidities, high-risk factors and foot disease complications. Recommendations have been
made to improve or remove identified weaker items for future QHRFF versions. Overall, the QHRFF possesses
suitable practicality, validity and reliability to assess and capture relevant foot disease items across multiple at risk
populations.
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Foot disease contributes to considerable hospitalisation
[1-4], amputation [5-8], institutionalisation [9,10], and
death [2,11]; yet foot disease complications and these
outcomes are largely preventable [5,6,12,13]. “High risk
factors” (such as peripheral neuropathy, peripheral arter-
ial disease or foot deformity) significantly increase the
risk of developing “foot disease complications” (such as
foot ulcers, infection or ischaemia) [1,14-16]. Diabetes
populations are frequently acknowledged as the leading
“at risk population” for foot disease due to the increased
risk of developing high risk factors, and in turn foot
disease complications, from diabetes [5-8,17]. However,
other chronic disease populations (such as chronic kid-
ney disease [15,16], cardiovascular disease [5,6,18,19] and
some cancers [5,6,8]) have now been shown to cause com-
parable rates of high risk factors and foot disease compli-
cations to diabetes, and thus, are also becoming more
readily identified as “at risk populations” for foot disease.
Best practice foot disease management has been shown
to significantly reduce hospitalisation, amputation, mortal-
ity and overall costs within different at risk populations
[5,12,13,20]. These multi-faceted best practice interven-
tions commonly include screening for high-risk factors,
multi-disciplinary management of foot disease complica-
tions, clinical training, evidence-based clinical pathway
utilisation and regular capture and analysis of foot disease
clinical data [5,6,12,13,20]. In consideration of the growing
problem of foot disease, and the potential future improve-
ments observed with best practice clinical management
and research, it is imperative that any clinical tools to as-
sess, capture, measure or analyse patient outcomes in at
risk populations are valid and reliable.
There are a multitude of studies that have investigated
a specific high risk foot factor or foot disease complication
within multiple at risk populations [3,5,6,21]. Furthermore,
numerous studies have investigated multiple high risk
factors and foot disease complications in specific at risk
populations such as diabetes [2,15,17]. However, very few
studies have investigated multiple high risk foot factors
and foot disease complications in multiple at risk popula-
tions. This situation appears to be mirrored by the clinical
tools available to measure and report on foot disease. For
example many validated single-item tools are available
which measure specific high-risk factors or foot disease
complications within multiple at risk populations [22-24];
such as the ankle brachial index to capture and measure
peripheral arterial disease within various at risk popula-
tions [22]. Furthermore, many validated multi-item tools
measuring multiple high-risk factors and foot disease
complications in specific at risk populations have been de-
veloped [15,25-28]; such as the University of Texas
Diabetic Foot Classification System to capture and meas-
ure multiple high risk factors and foot diseasecomplications in people with diabetes only [25]. However,
to the best of the authors’ knowledge a multi-item tool de-
signed to measure multiple high-risk factors and foot dis-
ease complications in multiple at risk populations is yet to
be developed and tested for validity and reliability.
Recently a Diabetic Foot Form (DFF) tool was developed
to measure multiple high-risk factors and foot disease
complications in people with diabetes only in diverse
Queensland (Australia) settings [29]. The DFF was a multi-
item tool developed from a number of existing clinical
tools recommended in the literature to reliably capture
various high-risk factors and foot disease complications
in the diabetes population [29]. The implementation of
the DFF in diverse Queensland clinical sites, in conjunc-
tion with other multi-faceted strategies, resulted in im-
proved capture, measurement and management of high
risk factors and foot disease complications and a corre-
sponding reduction in outcomes such as hospitalisation
and amputation [29,30]. However, the tool was not tested
for validity or reliability and was designed only to measure
multiple high-risk factors and foot disease complications
in the specific at risk population of people with diabetes.
In this study, we sought to modify the DFF tool to en-
able the measurement of multiple high risk factors and
foot disease complications in multiple at risk populations.
It was intended that the new multi-item tool would align
with best practice principles for clinical tools including be-
ing easily interpreted, practical to use and possessing high
face, content and criterion validity, and inter- and intra-
rater reliability [31-33]. Thus, the aims of this study were
firstly to develop a multi-item Queensland High Risk Foot
Form (QHRFF) tool to capture multiple high risk factors
and foot disease complications in multiple applicable at
risk populations, and secondly, to investigate the validity
and reliability of the tool’s individual items when used by
clinicians representing different levels of foot disease
expertise.
Methods
The study was conducted in two phases. Phase one in-
volved development of the Queensland High Risk Foot
Form (QHRFF) tool and phase two tested the validity and
reliability of the QHRFF tool. Approval was granted from
Institutional Ethics Committees and informed consent
was obtained from all individual participants (patients and
clinicians) for this study.
Phase one – development of the tool
Phase one primarily aimed to select items for the develop-
ment of a QHRFF tool that were practical to collect in an
Australian clinical setting, applicable to multiple ‘at risk’
populations, and provided high face and content validity.
The overarching procedures used for item selection in-
cluded using the original DFF [29] as the starting tool to
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for other recommended foot disease tools, establishing an
expert panel to guide development and using several
rounds of stakeholder consultation to refine the tool.
The original DFF contained 64 items pertaining to the
construct of foot disease in diabetes populations [29]
and was used as the starting tool to modify into the
QHRFF. The DFF was originally developed using similar
procedures to those used in this study and appeared to
possess high practicality, face and content validity [29].
Furthermore, the DFF had been routinely used in over
25 High Risk Foot Service sites throughout Queensland
for three years to collect standard clinical data on diabetes-
related foot disease [30].
An electronic literature search was undertaken of rele-
vant electronic databases including MEDLINE (all years to
June 2011), CINAHL (all years to June 2011) and relevant
professional websites to identify existing foot disease-
related tools. The basic terms searched included tools to
identify peripheral neuropathy, peripheral arterial disease,
foot deformity, foot ulceration, foot infection and amputa-
tion or synonyms.
An expert panel was established from members of the
Queensland Statewide Diabetes Foot Working Group; a
working group of the Queensland Statewide Diabetes
Clinical Network. The panel comprised 14 expert clini-
cians, with between five and 25 years of experience in
the area of foot disease management, from the fields of
endocrinology, vascular surgery, podiatry, nursing, pub-
lic health, quality improvement and research. The panel
had the responsibility to decide upon the final items for
the QHRFF tool after each round of consultation.
Refinements of the tool were achieved through numerous
rounds of consultation and trialling of draft QHRFF ver-
sions with external stakeholders in relation to practicality,
face and content validity. Stakeholders included up to 200
multidisciplinary professionals from sites registered to use
the existing DFF, members of the Queensland Health
Statewide Diabetes Clinical Network, Statewide Renal
Clinical Network and Statewide Podiatry Network.
At the conclusion of phase one the expert panel and
aforementioned network’s management committees deter-
mined, via consensus endorsement, that each item of the
QHRFF possessed high practicality, face and content valid-
ity, and was applicable across multiple ‘at risk’ populations
(particularly diabetes, cardiovascular disease and chronic
kidney disease) in Australian clinical settings. See Phase
One Results for further details regarding the final QHRFF.
Phase two – validity and reliability
The final endorsed QHRFF tool developed in phase one
was then tested for validity and reliability. The general
procedure for testing involved using podiatrists with dif-
ferent levels of foot disease expertise to assess patientswith different levels and severity of high risk factors and
foot disease. The authors decided to test only QHRFF
items that directly related to the foot disease construct,
thus, excluding items such as patients’ name, and facility.
To test the validity of each item a general criterion meas-
ure (the agreement between two ‘experts’) was initially
assessed for reliability. Each item was then tested, using
the podiatrists with different experience levels, against the
criterion measure to evaluate magnitudes of concurrent
criterion validity. The inter- and intra-rater reliability was
also tested for the level of agreement on each item by po-
diatrists with different levels of experience.
Setting and participants
The testing was conducted within the High Risk Foot
Services (HRFS), Metro North Hospital and Health
Service, Brisbane, Australia. Eligible clinician participants
were recruited from podiatrists practicing a minimum of
one session per week in a HRFS. Four podiatrists were
chosen as representative of the majority of clinicians man-
aging foot disease within Queensland Health, and thus,
potentially using the QHRFF in future. For the purposes
of the study, levels of expertise were categorised using the
Queensland Health ‘Health Practitioner award’ [34]. Thus,
expert clinicians were defined as either a ‘consultant clin-
ician’ (level 6) or ‘specialist clinician’ (level 5) [34] and
working in an acute hospital setting, plus, a member of
the expert panel to ensure they understood the original
intended construct for the QHRFF tool. General clinicians
were defined as a ‘senior clinician’ (level 4) or ‘clinician’
(level 3) [34], working in a community setting, and
thought to be representative of the general podiatry clin-
ical workforce managing foot disease in Queensland. One
of each level was recruited; one level 6, one level 5, one
level 4 and one level 3 (however, the level 3 had been act-
ing in a level 4 position at the time of the study). Written
informed consent was obtained from all participants
(patients and clinicians) prior to commencement of their
study participation.
Eligible patient participants were consecutively recruited
from patients already attending Community HRFS clinics
for the care of high risk factors or foot disease complica-
tions; defined as a previous or current foot ulcer. Exclu-
sion criteria included patients with a cognitive deficit,
signs or symptoms of a systemic infection, younger than
18 years of age, or unwilling to provide written consent to
participate. The authors considered that patients with pre-
vious or current foot ulcers would ensure that the majority
of high risk factors and foot disease items had the realistic
possibility of being present or absent, and thus, could be
suitably tested on each participant. Furthermore, it was
thought this population should possess the moderate
prevalence rates, yet unpredictable mixes and severities of
each item, of different high risk factors and foot disease
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prove statistical robustness for validity and reliability
studies [31].
Three different patient cohorts were used; one cohort to
test the reliability of the criterion measures (agreement be-
tween ‘experts’) (n = 32), another cohort to simultaneously
test the criterion validity (an ‘expert’ diagnosis againstFigure 1 Queensland high risk foot data collection form (QHRFF).general clinicians) and inter-rater reliability (n = 43), and
the last cohort to test the intra-rater reliability of a general
clinician (n = 19). The recruitment of consecutive commu-
nity patients did mean that patients may have been famil-
iar to the level 3 or level 4 clinicians; however, not to the
expert ‘gold standard’ clinicians working in the hospital
setting. To minimise the risk of patients being familiar to
Table 1 Supporting tools or literature for QHRFF items
QHRFF item Supporting tool or literature
General demographics* [35]
Indigenous status [14]
Health professionals attending* [14,39]
Medical co-morbidity history* [40,41]
Medical (diabetes) history [5-8]
Diabetes year diagnosed (duration) [17,42]




High-risk factor history* [14,35,39]
Clinical diagnoses of high-risk factors
Neuropathy Monofilament test
[1,14,23,39,44,45]
PAD Foot pulses, ankle brachial index
and/or toe systolic pressure
[1,14,21,22,39,46-49]
Acute Charcot [14,39]
Foot deformity Six-point foot deformity scale
[14,50]
Risk classification [14,39,51,52]
Clinical diagnoses of foot disease
(Ulcer) type [14,53,54]
Combined surface area mm2 [54-56]
Combined surface area (change since
last visit)
[55-59]
Clinical signs of infection [1,54,60,61]





*All items in this Domain cite the same references, unless otherwise stated.
#Ulcer depth was not specifically an item recorded on the QHRFF, but can be
directly extrapolated from the UTWCS Grade item.
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HRFS clinics were used to recruit patient participants.
The level 3 and level 4 clinicians had only worked at two
of the seven clinics recruiting patients.
Procedures
A designated research assistant coordinated all proce-
dures. Training of each clinician consisted of being pro-
vided with a QHRFF manual that gave a definition of
each item [35], a 1–2 hour training session on instruc-
tions and tips to use the QHRFF tool, and each was en-
couraged to trial the tool on their existing patients and
clarify any queries with the research assistant prior to
testing.
The general assessment procedure for each validity or
reliability test consisted of patients having their feet
examined by at least two different clinicians, blinded from
each other’s assessment, within the one clinical visit (valid-
ity and inter-rater reliability). However, to ensure all clini-
cians had an equal opportunity to determine the patient’s
debridement and wound management needs, all were per-
mitted to visually inspect the patient’s feet together for up
to five minutes prior to any clinician ratings. In this initial
inspection period, the clinicians were instructed to only
visually inspect the need for debridement and previous
wound dressings whilst not conversing with or touching
the patient or each other. The order of clinician assess-
ment after this inspection period was then at the dis-
cretion of the research assistant based on clinician
availability. The first clinician would have the additional
task of debriding the wound or callus if they deemed
necessary and the last clinician the additional task of
completing any clinical management.
The research assistant ensured all clinicians were
blinded from each other’s assessments in separate rooms
and that all examination records were de-identified.
Each clinician conducted the assessment of patient’s feet
using the QHRFF to record their assessment and man-
agement recommendations. Demographic, medical history
and medication information were available from the pa-
tients’ medical records or by direct communication with
the patients themselves. To minimise assessment bias all
historical foot-related records (including progress notes,
DFF tools or QHRFFs tools) were removed from the med-
ical record prior to each clinician’s assessment.
Criterion measure The criterion measure was tested on
the first cohort of patients. The criterion measure (i.e.
‘gold standard’ diagnosis) for each QHRFF item in this
study was defined by the authors as the diagnosis made
by an expert clinician. Expert clinicians were pragmatic-
ally chosen as a general criterion measure for all items,
instead of using multiple resource and time intensive
individual gold standard-recognised criterion measures(such as nerve conduction studies for neuropathy), due
to the resource and time constraints of the study. Best
practice dictates that any criterion measure should be
reliable, free from bias and measure the same item as
the new tool [31]. Thus, the study’s criterion measure, of
an expert clinician, required testing to determine its reli-
ability, independence (free from bias) and applicability,
prior to its use as a ‘gold standard’ criterion measure in
the criterion-related validity tests. The authors tested the
criterion measure by testing the reliability of the agree-
ment between two independent (blinded from one an-
other) experts (one level 6 and one level 5) to determine
the magnitude of reliability of agreement on their ‘gold
standard’ diagnoses for each item on the same patient
cohort. The “general assessment procedure” as described
Table 2 Demographic, co-morbidity and high-risk foot complication data for each patient cohort (n (%) unless
otherwise stated)
Criterion measure Criterion validity*
& inter-rater reliability*
Intra-rater reliability p Value
General demographics
Numbers 32 43 19
Male 25 (78%) 37 (86%) 17 (90%) 0.501
Age, mean (SD) (years)# 69 (13) 68 (13) 70 (15) 0.826
Age range (years) 48 – 90 36 – 89 42 – 90
Indigenous 1 (3%) 0 (0%) 1 (5%) NA
Health professionals attending (in the past week)
Podiatrist 32 (100%) 43 (100%) 19 (100%) 1.000
GP 2 (6%) 10 (23%) 2 (11%) 0.103
Nurse 3 (9%) 12 (28%) 4 (21%) 0.141
Orthotist 0 0 0 NA
Physician 2 (6%) 1 (2%) 1 (5%) NA
Surgeon 1 (3%) 3 (7%) 0 NA
Other 0 0 0 NA
Medical co-morbidity history
Diabetes (type 1 or 2) 28 (88%) 35 (81%) 16 (84%) 0.384
Type 2 diabetes 28 (88%) 31 (72%) 14 (74%) 0.256
Diabetes duration (years)# 12 (7) 23 (11) 20 (14) 0.001**
Recent BGLs > 15 mmol/L 5 (16%) 4 (9%) 5 (26%) 0.220
HbA1c (SD)# 9.2 (3.5) 8.1 (1.6) 8.4 (2.7) 0.450
Hypertension 28 (88%) 30 (70%) 11 (58%) 0.053
Dyslipidaemia 23 (72%) 25 (58%) 9 (47%) 0.201
Smoker 5 (16%) 11 (26%) 3 (16%) 0.492
CVD 21 (66%) 21 (49%) 9 (47%) 0.281
CKD 5 (16%) 13 (30%) 5 (26%) 0.339
ESRF 0 1 (2%) 0 NA
Other (non-listed) 29 (91%) 36 (84%) 11 (58%) 0.013**
High-risk history
Neuropathy 31 (97%) 37 (86%) 18 (95%) 0.214
PAD 14 (44%) 21 (49%) 8 (42%) 0.853
Previous foot ulcer 27 (84%) 37 (86%) 17 (90%) 0.878
Current foot ulcer 32 (100%) 42 (98%) 19 (100%) 0.549
New foot ulcer 21 (66%) 42 (98%) 19 (100%) ≤ 0.001**
Previous amputation 16 (50%) 17 (40%) 7 (37%) 0.566
Clinical diagnoses of high-risk factors
Neuropathy 31 (97%) 38 (88%) 19 (100%) 0.146
Any PAD 14 (44%) 22 (51%) 8 (42%) 0.735
Acute Charcot 1 (3%) 1 (2%) 0 NA
Foot deformity 26 (81%) 33 (77%) 17 (90%) 0.501
Acute risk classification 32 (100%) 42 (98%) 19 (100%) 0.549
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Table 2 Demographic, co-morbidity and high-risk foot complication data for each patient cohort (n (%) unless
otherwise stated) (Continued)
Clinical diagnoses of foot disease
Ulcer type: neuropathic 14 (44%) 14 (33%) 8 (42%) 0.572
Ulcer type: neuroischaemic 9 (28%) 16 (37%) 8 (42%) 0.555
Ulcer type: ischaemic 0 3 (7%) 1 (5%) NA
Ulcer type: other 9 (28%) 9 (21%) 2 (11%) 0.339
Combined surface area (mm2)# 122 (191) 352 (899) 379 (1436) 0.469
Any clinical infection 6 (19%) 14 (33%) 2 (11%) 0.125
UTWCS (Grade 1A) 13 (41%) 14 (33%) 7 (37%) 0.770
Deep ulcer (Grade 2 or 3)^ 8 (25%) 6 (14%) 2 (11%) 0.394
* = Same participants used for three tests.
** = Statistically significant (p < 0.05).
# = Measure in mean (standard deviation).
^ = Deep ulcer determined from the UTWCS Grade item.
NA = Not applicable to test as the assumption of Chi-squared test is violated as 2 cells had expected counts of < 5.
GP = General Practitioner; CVD = Cardiovascular Disease; ESRF = End Stage Renal Failure; PAD = Peripheral Arterial Disease; UTWCS = University of Texas Wound
Classification System.
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measure for each item was determined to be reliable, the
criterion validity of each QHRFF item was tested.
Criterion validity The criterion validity and inter-rated
reliability was then tested simultaneously on a second
cohort of patients. Criterion validity was tested using the
concurrent criterion validity method by comparing the
reliable criterion measure (one of the expert clinicians)
against each of the two representative ‘general’ clinicians
(one level 3 and one level 4). Thus, two separate criter-
ion assessments were carried out for each item; one
using the level 3 clinician against the criterion measure,
and another the level 4 clinician against the criterion
measure. Again the “general assessment procedure” as
described above was utilised for each patient when test-
ing for criterion validity.
Inter-rater reliability Inter-rater reliability tests were
performed simultaneously with the criterion validity tests
on the same second cohort of patients and were tested
using the expert clinician (level 5), senior clinician
(level 4) and clinician (level 3). Thus, three inter-rater reli-
ability measures of agreements were carried out for each
item; one testing the agreement between the level 5 and
level 4 clinician, a second between the level 5 and level 3
clinician, and a third between the level 4 and level 3 clin-
ician. “General assessment procedures” as described above
were again utilised for each patient when testing for inter-
rater reliability.
Intra-rater reliability Intra-rater reliability was tested
on a third cohort of patients. The clinician with the least
expertise (level 3) was used to test intra-rater reliability
as it was hypothesised that the clinician with the leastexpertise would have the most variability of the tested
clinicians. The two different time points to test intra-
rater reliability were between one and four weeks apart.
This time period was chosen as it was considered that a
minimum of one week (of full clinical load) would be
necessary to adequately reduce recall bias in a clinician,
plus, a maximum of four weeks would not be sufficient
time for the majority of items to markedly change and
thus items would remain stable between ratings. Any
items that did not fit this criteria were excluded from
intra-rater testing. Furthermore, this time period aligned
with any necessary follow up treatment time period for
patients, and thus, was convenient to patient partici-
pants. To control for any potential changes in foot ulcer
characteristics over time (for example ulcer combined
surface area and clinical signs of infection) digital images
were used. Digital photographic images taken of foot
ulcers at the first rating were used at the second rating
to standardise the foot ulcer characteristics across two
time points [36]. Images were taken perpendicular and
30-60 cm away from ulcers at the first rating, and incor-
porated two calibrated measures across the length and
width of the ulcer in the image. These images were
reviewed by the clinician at the second rating to deter-
mine the foot ulcer characteristics only.
Statistical analysis
All data was analysed using SPSS 19.0 for Windows
(SPSS Inc., Chicago, IL, USA) or GraphPad Software. De-
scriptive statistics were used to display the single demo-
graphic, medical co-morbidity, high-risk factors and foot
disease variables for each cohort of patient participants;
using means and standard deviations (SD) for continuous
variables (which were normally distributed) or proportions
for categorical variables. Each above descriptive cohort
Table 3 Criterion measure reliability – measure of agreement between gold standard experts
QHRFF item % K (SE) Strength of agreement [37]
General demographics
Indigenous status* 77.4 0.45 (0.17) Moderate
Health professionals attending (in the past week)
Podiatrist 96.9 – –
GP 81.2 0.78 (0.21) Substantial
Nurse 84.4 0.47 (0.18) Moderate
Orthotist 100 – –
Physician 96.9 0.78 (0.21) Substantial
Surgeon 100 1.00 (0.01) Near perfect
Other 100 – –
Medical co-morbidity history
Medical (diabetes) history 100 1.00 (0.01) Near perfect
Diabetes duration# 0.94 (0.88–0.98) Strong
Recent BGLs > 15 mmol/L* 90.6 0.81 (0.11) Near perfect
HbA1c result# 0.93 (0.79–0.98) Strong
Hypertension 87.5 0.60 (0.17) Moderate
Dyslipidaemia 75.0 0.46 (0.16) Moderate
Smoker 96.9 0.89 (0.11) Near perfect
CVD 93.8 0.86 (0.10) Near perfect
CKD 100 1.00 (0.01) Near perfect
ESRF 96.9 – –
Other (non-listed) 46.9 0.04 (0.09) Slight
High-risk history
Neuropathy 93.8 0.48 (0.31) Moderate
PAD 84.4 0.68 (0.13) Substantial
Previous foot ulcer 84.4 0.45 (0.21) Moderate
Current foot ulcer 96.9 – –
New foot ulcer 83.9 0.58 (0.15) Moderate
Previous amputation 90.6 0.81 (0.10) Near perfect
Clinical diagnoses of high-risk factors
Neuropathy 96.9 0.65 (0.32) Substantial
PAD* 77.4 0.61 (0.12) Substantial
Acute Charcot 100 1.00 (0.01) Near perfect
Foot deformity 81.3 0.46 (0.19) Moderate
Risk classification* 96.8 – –
Clinical diagnoses of foot disease
Ulcer type* 87.5 0.85 (0.08) Near perfect
Combined surface area mm2# 0.73 (0.52-0.86) Moderate
Clinical signs of infection* 84.3 0.68 (0.15) Substantial
UTWCS grade# 0.56 (0.28–0.76) Weak-moderate
Ulcer depth^ 78.1 0.67 (0.13) Substantial
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Table 3 Criterion measure reliability – measure of agreement between gold standard experts (Continued)
Clinical management principles performed
Debrided ulcer/callus* 93.8 – –
Dressing optimum* 96.9 – –
Antibiotics required* 84.4 0.47 (0.19) Moderate
Off-loading optimum* 68.8 0.41 (0.14) Moderate
Footwear optimum* 65.6 0.28 (0.16) Fair
Educated patient* 100 – –
K = Kappa; (SE) = Standard Error; % = Percentage agreement.
– = Measure of agreement was unable to be calculated because at least one variable was a constant.
GP = General Practitioner; CVD = Cardiovascular Disease; ESRF = End Stage Renal Failure; PAD = Peripheral Arterial Disease; UTWCS = University of Texas Wound
Classification System.
* = Weighted Kappa used for ordinal data.
# = Intraclass correlation (ICC) (Standard Deviation (SD)) for continuous data.
^ = Depth was determined from the UTWCS score.
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ise or on the first rating of the intra-rater reliability cohort.
Chi-squared test of independence and ANOVA were
used to test for differences between the three cohorts’
characteristics. A significance level of p < 0.05 was used
throughout.
All QHRFF items were tested for validity and reliability;
except those stated items considered not to impact on the
foot disease construct. Criterion validity was tested by cal-
culating sensitivity, specificity and positive predictive
values. Ordinal variables were collapsed into dichotomous
data to enable calculations of sensitivity, specificity and
positive predictive values. All measures of agreements
between clinicians were tested using Kappa (K) for di-
chotomous variables, weighted Kappa (wK) for ordinal
variables and intra-class correlation (ICCs) (model 2, 1)
for continuous variables [31,37,38]. Kappa and wK value
(Standard Errors (SE)) strengths were categorised as: no
agreement < 0; slight agreement = 0 – 0.20; fair agree-
ment = 0.21 - 0.40; moderate agreement = 0.41 – 0.6;
substantial agreement = 0.61 – 0.8; and near perfect
agreement = 0.81 – 1.0 [31,37,38]. ICC (SD) strengths
were categorised as: weak-moderate agreement < 0.75 and
strong agreement > 0.75 [31].
Results
Phase one – development of the tool
The literature search identified 174 papers that reported
on tools to identify or measure foot disease complications
and/or high-risk factors, with the majority of papers spe-
cifically relating to diabetes populations (90 (52%)).
Tools reported in other populations were in conditions
commonly identified in the literature to be associated
with lower limb amputation [5-8]. These included car-
diovascular disease (peripheral arterial disease), chronic
kidney disease, malignancy, infection and other neuro-
logical conditions [5-8]. No tool was identified that was
specifically designed to identify multiple high-riskfactors and foot disease complications in multiple at
risk populations.
Fifty-nine individual tools were identified from the lit-
erature search; 23 were considered to have adequate
practicality, face validity and applicability to an Australian
clinical context to be considered for the QHRFF. These
tools and the original DFF tool [29] were considered by
the expert panel for QHRFF item selection. At this
point, the expert panel determined that the tool should
be divided into a clinical assessment record section that
informed a separate data collection section, and thus,
only the data collection section would require testing.
Overall 87 items were initially identified from the con-
sidered tools. At the conclusion of phase one procedures
the final endorsed QHRFF data collection tool was made
up of 46-items (excluding general identification items)
covering seven domains (Figure 1). The seven content
domains included identifying general demographics, differ-
ent health professionals attending, medical co-morbidity
history, high-risk factor history, clinical diagnosis of high-
risk factors, clinical diagnoses of foot disease complica-
tions, and clinical management principles performed. A
QHRFF manual was developed to provide definitions and
instructions on each item contained in the tool [35].
Table 1 outlines the tools or literature used to support
each QHRFF item. At the conclusion of phase one, the ex-
pert panel concluded that the QHRFF tool’s items had the
required high clinical practicality, applicability to multiple
at risk populations, and good face and content validity.
Subsequently, the tool was endorsed for use by the
Queensland Health Statewide Diabetes, Renal and
Podiatry Clinical Networks. Thus, the tool was ready for
validity and reliability testing.
Phase two – validity and reliability
Forty items were tested for validity and reliability un-
less otherwise stated. The items not tested were those
considered not to impact on the foot disease construct;
Table 4 Criterion validity summary statistics for senior clinician (Sensitivity, specificity and positive predictive value) &
inter-rater reliability between expert and senior clinicians (Kappa and strength of agreement)




Specificity (95% CI) PPV (95% CI)
General demographics
Any indigenous status 100 – – – 1.00 (0.90-1.00) –
Health professionals attending (in the past week)
Podiatrist 100 – – 1.00 (0.90-1.00) – 1.00 (0.90-1.00)
GP 86.0 0.64 (0.14) Substantial 0.80 (0.44-0.96) 0.88 (0.71-0.96) 0.67 (0.35-0.88)
Nurse 93.0 0.83 (0.09) Near perfect 0.92 (0.60-1.00) 0.94 (0.77-0.99) 0.85 (0.54-0.97)
Orthotist 100 – – – 1.00 (0.90-1.00) –
Physician 93.0 – – 0 (0 – 0.95) 0.95 (0.83-0.99) 0 (0 – 0.80)
Surgeon 95.3 0.64 (0.24) Substantial 0.67 (0.13-0.98) 0.98 (0.85-1.00) 0.67 (0.13-0.98)
Other 100 – – – 1.00 (0.90-1.00) –
Medical co-morbidity history
Any medical (diabetes) history 100 1.00 (0.01) Near perfect 1.00 (0.88-1.00) 1.00 (0.60-1.00) 1.00 (0.88-1.00)
Diabetes duration# 0.90 (0.80– 0.95) Strong
Recent BGLs > 15 mmol/L 93.0 0.69 (0.16) Substantial 0.57 (0.20-0.88) 1.00 (0.88-1.00) 1.00 (0.40-1.00)
HbA1c result# 1.00 (0.99–1.00) Strong
Hypertension 93.0 0.83 (0.09) Near perfect 0.97 (0.81-1.00) 0.85 (0.54-0.97) 0.94 (0.77-0.99)
Dyslipidaemia 95.3 0.90 (0.07) Near perfect 0.96 (0.78-1.00) 0.94 (0.71-1.00) 0.96 (0.78-1.00)
Smoker 90.7 0.72 (0.13) Substantial 0.64 (0.32-0.88) 1.00 (0.87-1.00) 1.00 (0.56-1.00)
CVD 90.7 0.81 (0.09) Near perfect 0.86 (0.63-0.96) 0.95 (0.75-1.00) 0.95 (0.72-1.00)
CKD 81.4 0.49 (0.15) Moderate 0.46 (0.20-0.74) 0.97 (0.81-1.00) 0.86 (0.42-0.99)
ESRF 1.00 1.00 (0.01) Near perfect 1.00 (0.05-1.00) 1.00 (0.90-1.00) 1.00 (0.05-1.00)
Other (non-listed) 57.1 0.09 (0.12) Slight 0.57 (0.40-0.73) 0.57 (0.20-0.88) 0.87 (0.65-0.97)
High-risk history
Neuropathy 93.0 0.73 (0.15) Substantial 0.95 (0.80-0.99) 0.83 (0.36-0.99) 0.97 (0.84-1.00)
PAD 88.4 0.77 (0.10) Substantial 0.86 (0.63-0.96) 0.91 (0.69-0.98) 0.90 (0.67-0.98)
Previous foot ulcer 79.1 0.28 (0.18) Fair 0.84 (0.67-0.93) 0.50 (0.14-0.86) 0.91 (0.75-0.98)
Current foot ulcer 95.3 – – 0.98 (0.86-1.00) 0 (0 – 0.95) 0.98 (0.86-1.00)
New foot ulcer 93.0 – – 0.95 (0.82-0.99) 0 (0 – 0.95) 0.98 (0.86-1.00)
Previous amputation 97.7 0.95 (0.05) Near perfect 0.94 (0.69-1.00) 1.00 (0.84-1.00) 1.00 (0.76-1.00)
Clinical diagnoses of high-risk factors
Neuropathy 97.7 0.90 (0.10) Near perfect 0.97 (0.85-1.00) 1.00 (0.46-1.00) 1.00 (0.88-1.00)
Any PAD 93.0 0.86 (0.8) Near perfect 0.91 (0.69-0.98) 0.95 (0.74-1.00) 0.95 (0.74-1.00)
Acute Charcot 100 1.00 (0.01) Near perfect 1.00 (0.05-1.00) 1.00 (0.90-1.00) 1.00 (0.05-1.00)
Foot deformity 86.0 0.51 (0.16) Moderate 1.00 (0.87-1.00) 0.4 (0.14-0.73) 0.85 (0.69-0.94)
Acute risk classification 97.7 – – 1.00 (0.90-1.00) 0 (0 – 0.95) 0.98 (0.86-1.00)
Clinical diagnoses of foot disease
Ulcer type: neuropathic (neuropathic or neuroisch.) 90.7 0.76 (0.11) Substantial 0.88 (0.72-0.96) 1.0 (0.63-1.00) 1.00 (0.86-1.00)
Ulcer type: ischaemic 79.1 0.58 (0.13) Moderate 0.75 (0.51-0.90) 0.83 (0.60-0.94) 0.79 (0.54-0.93)
(Neuroisch. or ischaemic)
Combined surface area mm2# 0.93 (0.87–0.96) Strong
Any clinical infection 88.4 0.72 (0.12) Substantial 0.71 (0.42-0.90) 0.97 (0.80-1.00) 0.91 (0.57-1.00)
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Table 4 Criterion validity summary statistics for senior clinician (Sensitivity, specificity and positive predictive value) &
inter-rater reliability between expert and senior clinicians (Kappa and strength of agreement) (Continued)
UTWCS (Grade 1A) 83.7 0.65 (12) Substantial 0.85 (0.56-0.97) 0.83 (0.64-0.93) 0.71 (0.44-0.89)
Deep ulcer 95.3 0.81 (0.13) Near perfect 0.71 (0.30-0.95) 0.97 (0.84-1.00) 0.83 (0.36-0.99)
(Grade 2 or 3)^
Clinical management principles performed
Ulcer debridement is required 95.3 0.66 (0.01) Substantial 1.00 (0.89-1.00) 1.00 (0.20-1.00) 1.00 (0.89-1.00)
Dressing is optimum 100 – – 1.00 (0.90-1.00) – 1.00 (0.90-1.00)
Antibiotics are required 93.0 0.82 (0.10) Near perfect 0.83 (0.51-0.97) 0.94 (0.77-0.99) 0.83 (0.51-0.97)
Off-loading is optimum 93.0 0.80 (0.11) Substantial 0.80 (0.44-0.96) 0.97 (0.82-1.00) 0.89 (0.51-0.99)
Footwear is optimum 72.1 0.31 (0.16) Fair 0.50 (0.20-0.80) 0.82 (0.64-0.92) 0.45 (0.18-0.75)
Educated patient 97.7 – – 0.98 (0.86-1.00) – 1.00 (0.90-1.00)
K = Kappa; (SE) = Standard Error; % = Percentage agreement; PPV = Positive Predictive Value.
– = Measure of agreement was unable to be calculated because at least one variable was a constant.
GP = General Practitioner; CVD = Cardiovascular Disease; ESRF = End Stage Renal Failure; PAD = Peripheral Arterial Disease; UTWCS = University of Texas Wound
Classification System.
# = Intraclass correlation (ICC) (Standard Deviation (SD)) for continuous data.
^ = Depth was determined from the UTWCS score.
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ation status’, and ‘date of referral’. Table 2 displays the
general demographic, medical co-morbidity history,
high-risk factor history, clinical diagnoses of high-risk
factors and foot disease complications variable preva-
lence for the three patient cohorts used. No significant
differences were noted for these variables, except for
diabetes duration and any other co-morbidity (p < 0.05).
All cohorts contained variables with moderate prevalence
rates (> 15%) [31], except for different health professionals
attending previously, co-morbidity of end stage renal fail-
ure (ESRF), acute Charcot and ischaemic ulcers.
Criterion measure
Table 3 displays the reliability results for the criterion
measure of expert clinicians. Thirty-two items were able
to be statistically tested. Nine items (28%) recorded near
perfect categories of agreement, nine (28%) substantial/
strong categories, eleven (34%) moderate categories and
three (9%) weak/fair categories. Thus, overall 29 (91%) of
these items recorded at least a moderate category of reli-
ability (K > 0.4; ICC > 0.75). The items recording weaker
categories of reliability included other (non-listed) condi-
tion, University of Texas Wound Classification System
(UTWCS) grade and optimum footwear.
Criterion validity
Tables 4 and 5 display the criterion validity results for
both the senior (level 4) clinician and clinician (level 3)
respectively tested against the criterion measure for each
item. Thirty-six items were able to be statistically tested
for sensitivity, specificity or positive predictive values
(PPV) on both clinicians. Thus, 72 different tests were
each performed for sensitivity, specificity and PPV. Sixty-
one (85%), 59 (82%) and 60 (83%) items recorded at leastmoderate categories (> 0.7) for sensitivity, specificity and
PPV respectively. Conversely, three (8%), five (14%) and
four (11%) out of the 36 items recorded weak categories
(< 0.7) for sensitivity, specificity and PPV respectively on
both clinicians tested. The items registering weak categor-
ies of validity (sensitivity, specificity or PPV on both clini-
cians) included identifying a patient that had attended a
GP, physician or surgeon; chronic kidney disease (CKD) or
other (non-listed) condition; previous, current and new
foot ulcer all had poor specificity in particular; and
optimum footwear had poor PPVs.
Inter-rater reliability
Tables 4, 5 and 6 display the inter-rater reliability results
for all three tests. Ninety-six different tests were able to
be statistically tested for inter-rater reliability across the
three different pairs of clinician agreement. Twenty four
items (25%) recorded near perfect categories of agree-
ment, 43 (45%) substantial/strong categories, 17 (18%)
moderate categories and 12 (12%) weak/fair categories.
Thus, overall 84 (88%) of these items recorded at least
moderate categories of reliability (K > 0.4; ICC > 0.75).
The items recording weak categories of reliability across
two or more agreements tested included other (non-listed)
condition, previous foot ulcer and optimum footwear.
Intra-rater reliability
Table 6 also displays the intra-rater reliability results for
the level 3 clinician. The median (interquartile range)
period between the first and second ratings for the intra-
rater reliability testing was 2(1–2) weeks. Twenty-three
items were able to be statistically tested. Six items (26%)
recorded near perfect categories of agreement, ten (43%)
substantial/strong categories, four (17%) moderate cat-
egories and three (13%) weak/fair categories. Thus, overall
Table 5 Criterion validity summary statistics for clinician (Sensitivity, specificity and positive predictive value) &
inter-rater reliability between expert and clinician (Kappa and strength of agreement)
QHRFF field % K (SE) Strength of agreement [37] Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI)
General demographics
Any indigenous status 100 – – – 1.00 (0.90-1.00) –
Health professionals attending (in the past week)
Podiatrist 88.4 – – 0.88 (0.74-0.96) – 0.88 (0.74-0.96)
GP 81.4 0.39 (0.17) Fair 0.40 (0.14-0.73) 0.94 (0.78-0.99) 0.67 (0.24-0.94)
Nurse 79.1 0.37 (0.16) Fair 0.33 (0.11-0.65) 0.97 (0.81-1.00) 0.80 (0.30-0.99)
Orthotist 100 – – – 1.00 (0.90–1.00) –
Physician 97.6 0.66 (0.32) Substantial 1.00 (0.05-1.00) 0.98 (0.86-1.00) 0.50 (0.03-0.97)
Surgeon 90.7 0.45 (0.23) Moderate 0.67 (0.13-0.98) 0.93 (0.79-0.98) 0.40 (0.07-0.83)
Other 100 – – – 0.98 (0.86-1.00) –
Medical co-morbidity history
Any medical (diabetes) history 100 100 (0.01) Near perfect 1.00 (0.88-1.00) 1.00 (0.60-1.00) 1.00 (0.88-1.00)
Diabetes duration# 0.95 (0.90–0.97) Strong
Recent BGLs > 15 mmol/L 90.7 0.62 (0.17) Substantial 1.00 (0.40-1.00) 0.90 (0.75-0.97) 0.50 (0.17-0.83)
HbA1c result# 1.00 (0.99–1.00) Strong
Hypertension 86.0 0.68 (0.12) Substantial 0.87 (0.68-0.96) 0.85 (0.54-0.97) 0.93 (0.75-0.99)
Dyslipidaemia 79.1 0.58 (0.12) Moderate 0.76 (0.54-0.90) 0.83 (0.58-0.96) 0.86 (0.64-0.96)
Smoker 88.4 0.69 (0.13) Substantial 0.73 (0.39-0.93) 0.94 (0.78-0.99) 0.80 (0.44-0.96)
CVD 79.1 0.58 (0.12) Moderate 0.71 (0.48-0.88) 0.86 (0.64-0.96) 0.83 (0.58-0.96)
CKD 86.0 0.65 (0.13) Substantial 0.69 (0.39-0.90) 0.93 (0.76-0.99) 0.82 (0.48-0.97)
ESRF 97.7 0.66 (0.32) Substantial 1.00 (0.05-1.00) 0.98 (0.86-1.00) 0.50 (0.03-0.97)
Other (non-listed) 79.1 0.19 (0.19) Slight 0.89 (0.73-0.96) 0.29 (0.05-0.7) 0.86 (0.70-0.95)
High-risk history
Neuropathy 93.0 0.73 (0.15) Substantial 0.95 (0.80-0.99) 0.83 (0.36-0.99) 0.97 (0.84-1.00)
PAD 86.0 0.72 (0.10) Substantial 0.76 (0.52-0.91) 0.95 (0.75-1.00) 0.94 (0.69-1.00)
Previous foot ulcer 79.1 0.28 (0.18) Fair 0.84 (0.67-0.93) 0.50 (0.14-0.86) 0.91 (0.75-0.98)
Current foot ulcer 97.7 – – 1.00 (0.90-1.00) 0 (0 – 0.95) 0.98 (0.86-1.00)
New foot ulcer 97.4 – – 0.90 (0.76-0.97) 0 (0 – 0.95) 0.97 (0.85-0.99)
Previous amputation 95.3 0.90 (0.07) Near perfect 0.88 (0.62-0.98) 1.00 (0.84-1.00) 1.00 (0.75-1.00)
Clinical diagnoses of high-risk factors
Neuropathy 100 1.00 (0.01) Near perfect 1.00 (0.89-1.00) 1.00 (0.46-1.00) 1.00 (0.89-1.00)
Any PAD 95.3 0.91 (0.06) Near perfect 0.91 (0.69-0.98) 1.00 (0.81-1.00) 1.00 (0.80-1.00)
Acute Charcot 100 1.00 (0.01) Near perfect 1.00 (0.05-1.00) 1.00 (0.90-1.00) 1.00 (0.05-1.00)
Foot deformity 93.0 0.80 (0.11) Substantial 0.97 (0.82-1.00) 0.80 (0.44-0.96) 0.94 (0.79-0.99)
Acute risk classify 97.7 – – 1.00 (0.90-1.00) 0 (0 – 0.95) 0.98 (0.86-1.00)
Clinical diagnoses of foot disease
Ulcer type: neuropathic 83.7 0.55 (0.14) Moderate 1.00 (0.86-1.00) 0.46 (0.20-0.74) 0.81 (0.64-0.91)
(Neuropathic or neuroisch.)
Ulcer type is ischaemic 79.1 0.57 (0.13) Moderate 0.74 (0.48-0.90) 0.83 (0.62-0.95) 0.78 (0.52-0.93)
(Neuroisch. or ischaemic)
Combined surface area mm2# 0.99 (0.99–1.00) Strong
Any clinical infection 81.4 0.58 (0.13) Moderate 0.71 (0.42-0.90) 0.86 (0.67-0.95) 0.71 (0.42-0.90)
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Table 5 Criterion validity summary statistics for clinician (Sensitivity, specificity and positive predictive value) &
inter-rater reliability between expert and clinician (Kappa and strength of agreement) (Continued)
UTWCS (Grade 1A) 81.4 0.61 (0.12) Substantial 0.86 (0.56-0.97) 0.79 (0.60-0.91) 0.69 (0.41-0.86)
Deep ulcer 93.0 0.73 (0.15) Substantial 0.71 (0.30-0.95) 0.97 (0.84-1.00) 0.83 (0.36-0.99)
(Grade 2 or 3)^
Clinical management principles performed
Ulcer debridement is required 95.3 0.39 (0.22) Fair 1.00 (0.89-1.00) 0.50 (0.03-0.97) 0.98 (0.86-1.00)
Dressing is optimum 97.7 – – 0.98 (0.86-1.00) – 1.00 (0.90-1.00)
Antibiotics are required 90.7 0.76 (0.11) Substantial 0.75 (0.43-0.93) 0.97 (0.81-1.00) 0.90 (0.54-0.99)
Off-loading is optimum 79.1 0.50 (0.14) Moderate 0.80 (0.44-0.96) 0.79 (0.60-0.90) 0.53 (0.27-0.78)
Footwear is optimum 79.1 0.47 (0.15) Moderate 0.70 (0.35-0.92) 0.82 (0.64-0.92) 0.54 (0.26-0.80)
Educated patient 100 – – 1.00 (0.90-1.00) – 1.00 (0.90-1.00)
K = Kappa; (SE) = Standard Error; % = Percentage agreement; PPV = Positive Predictive Value.
– = Measure of agreement was unable to be calculated because at least one variable was a constant.
GP = General Practitioner; CVD = Cardiovascular Disease; ESRF = End Stage Renal Failure; PAD = Peripheral Arterial Disease; UTWCS = University of Texas Wound
Classification System.
*= Weighted Kappa used for ordinal data.
# = Intraclass correlation (ICC) (Standard Deviation (SD)) for continuous data.
^ = Depth was determined from the UTWCS score.
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egory of reliability (K > 0.4; ICC > 0.75). Those items scor-
ing weak categories of agreement were foot deformity,
optimal offloading and optimal footwear.
Discussion
The QHHRF appears to be the first multi-item tool
developed and tested to identify multiple high-risk factors
and foot disease complications in multiple at risk popula-
tions. Our findings indicate that the majority of the tool’s
items demonstrates at least moderate categories of validity
(face, content and criterion validity) and reliability (inter-
rater and intra-rater); particularly those in the domains of
identifying relevant medical co-morbidity history, and
clinical diagnoses of high-risk factors and foot disease
complications. However, some items in the domains of
identifying different health professionals previously at-
tending the patient and general clinical management
principles performed appear to have weaker categories
of validity and reliability that need addressing in future
versions of the tool.
The QHRFF went through a number of developmental,
validity and reliability tests to determine its status as a
valid and reliable tool. The magnitude of validity (or ac-
curacy) in this study was evaluated via the methods of
face, content and importantly criterion validity. Face
and content validity are considered the least robust of
the validity tests due to their inherent subjectivity [31,33].
However, they are considered important factors in the de-
velopment phase to ensure the tool can actually measure
the general identified construct [31,33]; in this case foot
disease. At the completion of phase one, the expert panel
and network stakeholders endorsements implied high
practicality, face and content validity.Criterion validity is considered to be the most objective
validity test [31,33]. To test concurrent criterion validity,
as used by this study, a satisfactory criterion measure must
be used. In this study the criterion measure to test criter-
ion validity was an expert’s clinical diagnosis. Overall, the
‘expert’ criterion measure used for this study were rated as
having at least moderate categories of reliability for all but
three items; any other (non-listed) co-morbidity, optimum
footwear and UTWCS grade. The other (non-listed) co-
morbidity and optimum footwear items rated in the weak
categories in most other inter- or intra-rater reliability
agreement tested and should be reviewed or removed in
future versions of the QHRFF. The weak-moderate agree-
ment for the UTWCS grade was unexpected as this tool
has been validated extensively in the past [62], however, all
other inter- or intra-rater agreements on the UTWCS
were rated as substantial/strong categories of reliability.
Thus, it is recommended that the UTWCS grade be
retained in future with more emphasis applied on the
UTWCS grading system in the training sessions provided.
It is certainly possible that the criterion measure for each
item may have been more robust if the individual gold
standard test for each individual item were used; for ex-
ample an angiogram to diagnose peripheral arterial disease
[22] or nerve conduction studies to diagnose neuropathy
[44]. However, such an approach would have been particu-
larly resource and time intensive and was thus not prac-
tical within the resources available to this study.
The QHRFF items were tested for concurrent criterion
validity by using two different blinded representative gen-
eral clinicians’ ratings compared to the criterion measure
(a reliable expert’s diagnosis) on the same patients. Positive
predictive values from this testing indicated the majority
of QHRFF items had at least moderate validity when used
Table 6 Reliability measure of agreement summary statistics: Inter-rater (Senior clinician & clinician) & intra-rater
(Clinician)
Inter-rater reliability Intra-rater reliability
QHRFF field % K (SE) Strength of agreement [37] % K (SE) Strength of agreement [37]
General demographics
Indigenous status* 83.7 – – 100 1.00 (0.01) Near Perfect
Health professionals attending (in the past week)
Podiatrist 88.4 – – N/A N/A N/A
GP 81.4 0.45 (0.15) Moderate N/A N/A N/A
Nurse 81.4 0.47 (0.14) Moderate N/A N/A N/A
Orthotist 100 – – N/A N/A N/A
Physician 90.7 – – N/A N/A N/A
Surgeon 90.7 0.45 (0.23) Moderate N/A N/A N/A
Other 97.7 – – N/A N/A N/A
Medical co-morbidity history
Medical (diabetes) history 95.3 0.94 (0.05) Near perfect 100 1.00 (0.01) Near Perfect
Diabetes duration# 0.94 (0.87–0.97) Strong 1.00 (0.99–1.00) Strong
Recent BGLs >15 mmol/L* 83.7 0.67 (0.12) Substantial N/A N/A N/A
HbA1c result# 1.00 (1.00–1.00) Strong 1.00 (1.00–1.00)
Hypertension 88.4 0.73 (0.11) Substantial 89.5 0.78 (0.15) Substantial
Dyslipidaemia 83.7 0.67 (0.11) Substantial 94.7 0.90 (0.10) Near Perfect
Smoker 88.4 0.64 (0.15) Substantial 94.7 0.83 (0.17) Near Perfect
CVD 88.4 0.76 (0.10) Substantial 84.2 0.69 (0.17) Substantial
CKD 86.1 0.58 (0.15) Moderate 94.7 0.86 (0.14) Near Perfect
ESRF 97.7 0.66 (0.32) Substantial 100 – –
Other (non-listed) 69.1 0.34 (0.11) Fair 78.9 0.57 (0.19) Moderate
High-risk history
Neuropathy 90.7 0.66 (0.16) Substantial 94.7 – –
PAD 83.7 0.67 (0.11) Substantial 78.9 0.60 (0.16) Moderate
Previous foot ulcer 90.7 0.72 (0.13) Substantial 94.7 0.64 (0.33) Substantial
Current foot ulcer 97.7 – – 100 – –
New foot ulcer 97.4 – – 100 – –
Previous amputation 97.7 0.95 (0.05) Near perfect 100 1.00 (0.01) Near Perfect
Clinical diagnoses of high-risk factors
Neuropathy 97.7 0.90 (0.10) Near perfect 94.7 – –
PAD* 97.9 0.97 (0.03) Near perfect 84.2 0.69 (0.16) Substantial
Acute charcot 100 1.00 (0.01) Near perfect 100 – –
Foot deformity 83.7 0.38 (0.18) Fair 84.2 0.31 (0.30) Fair
Risk classification 100 – – 100 – –
Clinical diagnoses of foot disease
Ulcer type* 88.4 0.81 (0.08) Near perfect 84.2 0.77 (0.14) Substantial
Combined surface area mm2# 0.94 (0.89–0.97) Strong 1.00 (1.00–1.00) Strong
Clinical signs infection* 76.7 0.60 (0.12) Moderate 89.5 0.46 (0.32) Moderate
UTWCS grade# 0.90 (0.83–0.95) Strong 0.98 (0.94–0.99) Strong
Ulcer depth^ 95.3 0.90 (0.10) Near perfect 94.7 0.79 (0.23) Substantial
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Table 6 Reliability measure of agreement summary statistics: Inter-rater (Senior clinician & clinician) & intra-rater
(Clinician) (Continued)
Clinical management principles performed
Debrided ulcer/callus* 97.7 0.66 (0.32) Substantial 94.7 – –
Dressing optimum* 97.7 – – 100 – –
Antibiotics required* 79.1 0.54 (0.12) Moderate 89.5 0.44 (0.33) Moderate
Off-loading optimum* 72.1 0.36 (0.13) Fair 68.4 0.32 (0.23) Fair
Footwear optimum* 67.4 0.33 (0.14) Fair 68.4 0.37 (0.21) Fair
Educated patient* 97.7 – – 89.5 – –
K = Kappa; (SE) = Standard Error; – = Measure of agreement was unable to be calculated because at least one variable was a constant.
GP = General Practitioner; CVD = Cardiovascular Disease; ESRF = End Stage Renal Failure; N/A = Not applicable to test due to unstable rating environment; PAD =
Peripheral Arterial Disease; UTWCS = University of Texas Wound Classification System.
*= Weighted Kappa used for ordinal data;
# = Intraclass correlation (ICC) (Standard Deviation (SD)) for continuous data.
^ = Depth was determined from the UTWCS score.
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positive predictive values suggest that the proportion of
people with a positive test result for individual QHRFF
items actually had the relevant medical co-morbidity,
high-risk factor or foot disease complication of inter-
est. Although there were a few notable exceptions such
as identifying different health professionals attending
previously, recent blood glucose levels (BGLs) > 15 mmol/L,
ESRF, optimal offloading and optimum footwear. How-
ever, overall the QHRFF tool appears to demonstrate
acceptable validity in the majority of its items to be con-
sidered a valid tool to test the foot disease construct in
multiple at risk populations.
Reliability (or consistency) is a major prerequisite of any
useful items to be measured [31,33]. In this study inter-
rater and intra-rater measures of agreement were used for
reliability. Inter-rater reliability was primarily assessed
using three clinicians with different representative levels
of expertise in managing foot disease. Overall, all items
consistently displayed at least moderate categories of reli-
ability, except for any other (non-listed) co-morbidity,
optimum footwear and previous foot ulcer. Optimum
footwear was also identified to have weak categories of
intra-rater reliability; along with identifying foot deformity
and optimum offloading. Thus, the QHRFF tool appears
to demonstrate satisfactory reliability to collect the ma-
jority of items in the foot disease construct. However,
the authors recognise that it would have been preferable
to test reliability with more clinicians across a larger
sample of patients, yet this was beyond the resourcing
available for this study.
Notwithstanding, the aforementioned methodological
limitations, the study does incorporate many best practice
research design methods for testing validity and reliability.
These methods included testing the reliability of the cri-
terion measure to diagnose and measure each item, testing
the subsequent concurrent criterion validity of representa-
tive clinicians, and testing the reliability of the tool whenused by clinicians with different levels of expertise.
Furthermore, the study employed patient samples that
were highly representative of the demographics and
co-morbidity prevalence rates found in multiple ‘at
risk’ populations for high risk factors and foot disease
complications. These high prevalence rates not only
suggest the tool was tested in the construct it was de-
signed to measure, but literature suggests higher preva-
lence rates improve the statistical robustness of validity
and reliability results [31]. Lastly, many existing validated
single-item tools [23,46,60,62] were incorporated within
the QHRFF tool and this potentially adds weight to the
validity reported in this study. Thus, overall the QHRFF
tool appears to be a valid and reliable tool to collect the
vast majority of items contained within the foot disease
construct and can be used as a general tool to comple-
ment existing specific tools in the field of foot disease.
Limitations
Several limitations have already been outlined in this
study including the use of a general criterion measure of
an experts’ clinical diagnoses for each item, only using a
limited number of representative clinicians and testing
intra-rater reliability on one clinician in a small sample.
Other limitations include: not performing a systematic
literature review (and thus some evidence based items
and tools may have been overlooked); using only podia-
trists as the clinical raters; using historically defined
strength categories for validity and reliability; not testing
the tool for construct validity, predictive validity, or fac-
tor analysis; and the settings used were existing HRFS
only. It is recommended that any future research into
this tool should address these methodological limitations
by investigating the factor analysis, construct and pre-
dictive criterion validity of the tool’s items in a much
larger and broader sample of patients with more multi-
disciplinary clinician raters. Furthermore, if resources
permit, the use of individual gold standard criterion
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item tools should be considered.
However, there are a number of recommendations from
this study’s findings that should be considered for imple-
mentation in future versions of the QHRFF tool. Firstly,
those items reporting weaker categories of validity or reli-
ability and that potentially collect duplicate information to
other more reliable items should be removed; including
any other (non-listed) co-morbidity, combined surface
area (change), recent BGLs greater than 15 mmol/L and
new ulcer. Secondly, some items’ definitions should be
reviewed in an attempt to improve the item’s future reli-
ability and validity. For example, previous foot ulcer
definition could be modified to identify a previously
“healed” foot ulcer, ‘health professionals attending’ pre-
viously requires an exact retrospective time period that
patients were in attendance in alignment with similar
literature (such as “in the previous two weeks”) [64,65]
and optimum offloading should have a more explicit
definition referring directly to non-removable offload-
ing definitions in the existing literature [14]. Thirdly,
the validation of criteria for identifying a foot deformity
and optimum footwear are urgently required for these
‘at risk’ populations. To the best of the author’s knowledge
such tools for these items have been developed [14,50] yet
are to be validated and this study was no exception. How-
ever, in the meantime the authors recommend adding the
numerical foot deformity score to the QHRFF to improve
accuracy and test for validity. Lastly, a systematic literature
review for other reported independent associates for
foot disease (such as cancer, arthritis, depression, trauma,
vision impairment, mobility impairment and social deter-
minant factors) and other outcome measures for foot dis-
ease (such as quality of life measures) should be performed
to ensure all ‘at risk’ populations and outcome measures
for foot disease are identified, considered and potentially
included in the next QHRFF version.
Conclusions
The QHRFF tool appears to be the first multi-item tool
developed and tested to identify multiple high-risk factors
and foot disease complications in multiple at risk popu-
lations. Acceptable validity and reliability were demon-
strated for the majority of items; particularly in the
domains of identifying relevant medical co-morbidity
history and clinically diagnosing high-risk factors and
foot disease complications. However, recommendations
to remove, add or redefine items registering weak validity
or reliability scores should be implemented to improve
future versions of the QHRFF tool; particularly in the
domains of health professionals attending and clinical
management principles. Overall, the QHRFF tool ap-
pears to demonstrate the practicality, validity and reli-
ability required to facilitate robust clinical assessmentand data capture to measure the large burden of foot
disease facing our multiple at risk populations.
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